French study finds that targeting DprE1 to treat Tuberculosis can overcome drug resistance issues
Nikhil Prasad Fact checked by:Thailand Medical News Team Aug 27, 2024 2 weeks, 4 days, 4 hours, 49 minutes ago
TB News: The global health crisis caused by COVID-19 has overshadowed many ongoing battles in the medical world, one of which is the persistent and deadly threat of tuberculosis (TB). TB continues to claim lives, particularly in underdeveloped regions, where it remains a significant challenge. Researchers from Aix Marseille University, France, are leading efforts to combat this disease by focusing on a promising target within the TB bacterium, Mycobacterium tuberculosis (Mtb). This
TB News report delves into the recent discoveries surrounding DprE1, a critical enzyme in Mtb, and the development of new drugs aimed at inhibiting its function.
French study finds that targeting DprE1 to treat Tuberculosis can overcome drug resistance issues.
The Urgent Need for New TB Treatments
Tuberculosis remains one of the deadliest infectious diseases, killing over 1.6 million people in 2021 alone. Despite the availability of treatments, the rise of drug-resistant strains of TB, including multi-drug-resistant (MDR) and extensively drug-resistant (XDR) TB, has made the fight against this disease more challenging.
The standard treatment regimen, which includes a combination of drugs such as isoniazid and rifampicin, is becoming less effective due to increasing resistance.
The researchers from Aix Marseille University in France have identified DprE1 as a key enzyme in the survival of Mtb, making it a prime target for new drug development. The study explores the significance of DprE1 in TB pathogenesis and the potential of DprE1 inhibitors to revolutionize TB treatment.
Understanding DprE1: A New Target in TB Therapy
DprE1, or decaprenylphosphoryl-β-D-ribose oxidase, is an enzyme involved in the synthesis of decaprenylphosphoryl-arabinofuranose (DPA), a crucial component of the mycobacterial cell wall. The integrity of the cell wall is vital for the survival and virulence of Mtb, making DprE1 a critical target for new TB drugs.
Current research has shown that inhibiting DprE1 disrupts the synthesis of DPA, leading to the weakening of the mycobacterial cell wall and ultimately the death of the bacteria. This makes DprE1 an attractive target for novel anti-TB agents, especially in the face of rising drug resistance.
Key Findings from Recent Studies
Recent studies have focused on the development of DprE1 inhibitors, with several promising candidates currently in clinical trials. These include Macozinone, BTZ-043, TBA-7371, and OPC-167832. Each of these compounds has shown potent activity against Mtb, including drug-resistant strains.
Macozi-none, for example, has demonstrated exceptional efficacy in preclinical trials, with a minimum inhibitory concentration (MIC) as low as 0.65 nM. This compound works by forming a covalent bond with the DprE1 enzyme, effectively blocking its function. BTZ-043, another DprE1 inhibitor, has also shown promising results, with a MIC of 2.3 nM and low toxicity in human cells.
&
nbsp;
The study highlights the critical role of DprE1 in the survival of Mtb. By targeting this enzyme, researchers hope to develop new treatments that are effective against both drug-sensitive and drug-resistant strains of TB.
One of the key challenges in developing DprE1 inhibitors is ensuring that these drugs are safe for human use. Since DprE1 is unique to mycobacteria and absent in humans, there is a reduced risk of toxicity, making it an ideal target. The ongoing clinical trials aim to further assess the safety and efficacy of these inhibitors, with the hope of bringing a new class of TB drugs to market.
Conclusion
The research into DprE1 inhibitors represents a significant step forward in the fight against tuberculosis. By targeting a critical enzyme in the mycobacterial cell wall, these new drugs have the potential to overcome the challenges posed by drug-resistant TB strains. The findings from this study underscore the importance of continued research and development in this area, as new treatments are desperately needed to address the global TB crisis.
The study findings were published in the peer-reviewed journal: BioMed.
https://www.mdpi.com/2673-8430/4/3/18
For the latest
TB News, keep on logging to Thailand Medical News.
Read Also:
https://www.thailandmedical.news/news/new-bioaerosol-study-challenges-previous-notions-about-tuberculosis-spread-and-transmission
https://www.thailandmedical.news/news/tuberculosis-survivors-face-elevated-risk-of-heart-disease
Share
Tweet
Share
